Madrigal posts corporate presentation; full content not visible in filing text

MADRIGAL PHARMACEUTICALS, INC.

Madrigal posted a corporate presentation to its website for investor communications on January 8, 2024.
The presentation describes resmetirom as an investigational therapy not yet approved by FDA.
No specific new data or financial updates were extracted from the provided exhibit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.